Nerlynx (Neratinib Maleate) Patent Expiration, LOE Window & CMS Spending

Nerlynx (Neratinib Maleate) by Puma Biotechnology: FDA Orange Book core substance LOE 2030-12-29 (last listed 2031-07-18), 0 AB generics, $60.6M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPuma Biotechnology
FDA Application & PathwayN208051 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2030-12-29
Last Listed Patent or Exclusivity Date2031-07-18
Orange Book Patents (*PED Extensions)9 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$60.6M
2024 Medicare Part D Spend$38.4M
2024 Medicaid Spend$22.2M
Reported Wholesale Price Change (CA SB 17)8 WAC filings (max 24.0% 2-yr change)